Abstract:Background Antitumor therapeutic vaccines are generally based on antigenic epitopes presented by major histocompatibility complex (MHC-I) molecules to induce tumor-specific CD8 + T cells. Paradoxically, continuous T cell receptor (TCR) stimulation from tumor-derived CD8 + T-cell epitopes can drive the functional exhaustion of tumor-specific CD8 + T cells. Tumor-specific type-I helper CD4 + T (T H 1) cells play an important role in the population maintenance and cytotoxic function of exhausted tumor-specific CD8 + T cells in the tumor microenvironment. Nonetheless, whether the vaccination strategy targeting MHC-II-restricted CD4 + T-cell epitopes to induce tumor-specific T H 1 responses can confer effective antitumor immunity to restrain tumor growth is not well studied. Here, we developed a heterologous prime-boost vaccination strategy to effectively induce tumor-specific T H 1 cells and evaluated its antitumor efficacy and its capacity to potentiate PD-1/PD-L1 immunotherapy. Methods Listeria monocytogenes vector and influenza A virus (PR8 strain) vector stably expressing lymphocytic choriomeningitis virus (LCMV) glycoprotein-specific I-A b -restricted CD4 + T cell epitope (GP 61–80 ) or ovalbumin-specific CD4 + T cell epitope (OVA 323-339 ) were constructed and evaluated their efficacy against mouse models of melanoma and colorectal adenocarcinoma expressing lymphocytic choriomeningitis virus glycoprotein and ovalbumin. The impact of CD4 + T cell epitope-based heterologous prime-boost vaccination was detected by flow-cytometer, single-cell RNA sequencing and single-cell TCR sequencing. Results CD4 + T cell epitope-based heterologous prime-boost vaccination efficiently suppressed both mouse melanoma and colorectal adenocarcinoma. This vaccination primarily induced tumor-specific T H 1 response, which in turn enhanced the expansion, effector function and clonal breadth of tumor-specific CD8 + T cells. Furthermore, this vaccination strategy synergized PD-L1 blockade mediated tumor suppression. Notably, prime-boost vaccination extended the duration of PD-L1 blockade induced antitumor effects by preventing the re-exhaustion of tumor-specific CD8 + T cells. Conclusion CD4 + T cell epitope-based heterologous prime-boost vaccination elicited potent both tumor-specific T H 1 and CTL response, leading to the efficient tumor control. This strategy can also potentiate PD-1/PD-L1 immune checkpoint blockade (ICB) against cancer.

PD-L1 Antibodies-Armed Exosomal Vaccine for Enhanced Cancer Immunotherapy by Simultaneously in Situ Activating T Cells and Blocking PD-1/PD-L1 Axis

Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment

Combination of GNRs-PEI/cGAMP-laden Macrophages-Based Photothermal Induced in Situ Tumor Vaccines and Immune Checkpoint Blockade for Synergistic Anti-Tumor Immunotherapy.

Gene Engineered Exosome Reverses T Cell Exhaustion in Cancer Immunotherapy

Enhancedanti-tumor efficacy through a combination of intramuscularly expressed DNA vaccine and plasmid-encoded PD-1 antibody

Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l -Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade

Therapeutic exosomal vaccine for enhanced cancer immunotherapy by mediating tumor microenvironment

Exosomes derived from immunogenically dying tumor cells as a versatile tool for vaccination against pancreatic cancer

CD4 + T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy

A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory

A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy

A cascade targeting strategy based on modified bacterial vesicles for enhancing cancer immunotherapy

PD‐1 Blockade Cellular Vesicles for Cancer Immunotherapy

Engineered Antler Stem Cells Derived Exosomes Potentiate Anti-Tumor Efficacy of Immune Checkpoint Inhibitor by Reprogramming Immunosuppressive Tumor Microenvironment

A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model

Engineering Chameleon Prodrug Nanovesicles to Increase Antigen Presentation and Inhibit PD‐L1 Expression for Circumventing Immune Resistance of Cancer

Extracellular vesicles hybrid plasmid-loaded lipid nanovesicles for synergistic cancer immunotherapy

Antigen-specific Bacterial Vaccine Combined with Anti-Pd-l1 Rescues Dysfunctional Endogenous T Cells to Reject Long-Established Cancer.

A combination strategy based on an Au nanorod/doxorubicin gel via mild photothermal therapy combined with antigen-capturing liposomes and anti-PD-L1 agent promote a positive shift in the cancer-immunity cycle

Tumor-repopulating cell-derived microparticles elicit cascade amplification of chemotherapy-induced antitumor immunity to boost anti-PD-1 therapy